In the last five years, it has become apparent that dopamine, once regarded simply as a metabolic precursor of noradrenaline and adrenaline, has an important part to play in physiological regulation outside the central nervous system. Specific, highly selective receptors for dopamine have been identified in the peripheral and mesenteric arterioles, the sympathetic ganglia and the renal circulation. Perhaps more important, it has now been demonstrated conclusively that the kidney can produce dopamine and that this substance may act intrarenally as a natriuretic hormone.
Action of Inttsed dopamine on the kidney
Our knowledge of this subject stems from the pioneer work of Leon Goldberg over a period of 20 years. Much of this information he summarized in 1972 [ l l and 1978 [21.
Dopamine acts on at least three types of vascular receptor: the a-adrenoceptor, the padrenoceptor and a specific dopamine receptor. Stimulation of the a-adrenoceptor generally leads to vasoconstriction whereas stimulation of either the B-adrenoceptor or the dopamine receptors usually leads to vasodilatation. The vasodilatation induced by dopamine is not due to an action on other vasodilator systems such as the kallikrein-kinin system or the prostaglandins. The dopamine receptors have precise chemical structural requirements and they may be selectively activated (or blocked) by suitable agonists (or antagonists). They are not distributed uniformly throughout the cardiovascular system but are located mainly in the cardiac, coeliac, 
Action of dopamine in the kidney
In pharmacological doses dopamine is a potent natriuretic and vasodilator agent 151. The mechanisms of this natriuretic action appear to be multiple; dopamine increases renal plasma flow and glomerular filtration rate, induces a redistribution of intyenal blood flow 161 and inhibits the tubular transport of sodium 171. Dopamine infusion also increases urine cyclic AMP excretion in man and this effect parallels the increased rejection of sodium into the renal tubules 181. Both /3-adrenoceptor stimulation and cyclic AMP have been shown to decrease proximal tubular reabsorption of sodium and it is possible that the natriuretic effect of dopamine is a combination of an action on padrenoceptors and also on more specific renal vascular and tubular dopaminergic receptors. Inhibitors have been identified which selectively block the vasodilator response to dopamine or dopamine-like agonists. The most potent of these inhibitors is sulpiride, but others which are effective include bulbocapnine, haloperidol and metoclopramide. Specific dopamine-binding sites have also been identified in renal tissue 191.
A number of reports have appeared that dopamine infusion may be helpful in clinical situations characterized by oliguria, presumably by reversing the afferent glomerular arteriolar vasoconstriction thought to be important in the pathogenesis of acute renal failure [ 10-121.
Casson and I have also demonstrated recently that y-glutamyl dopa, a renal prodrug for the dopamine receptors, can protect against the full effects of glycerol-induced acute renal failure in the rat (I. F. Casson & M. R. Lee, unpublished work) . These observations, taken together with the beneficial effect of dopamine pretreatment on the kidneys of unstable kidney donors 131, would suggest that dopamine, a dopamine agonist or a dopamine prodrug might be of benefit in patients at risk of acute oliguric renal failure after elective surgery. It should be noted that in some of these regimens dopamine has been combined with frusemide, and the latter compound has been shown to be capable of eliciting an increase in urine free dopamine [ 
141.

Dopamine in the urine
The amount of dopamine excreted in human urine is from 5 to 20 times greater than the amount of noradrenaline [15]. Initially the assumption was made that this reflected the filtered load of dopamine and was derived from the plasma. However, when sensitive and specific radioisotopic techniques became available for the determination of plasma catecholamine levels, it became apparent that urine dopamine was vastly greater than could be accounted for by filtered plasma dopamine.
Da [ 181 determined plasma and urine free dopamine simultaneously in six normal subjects and calculated a mean urinary clearance for dopamine of 1996 k 453 ml/min (range 402-3844 ml/min), greatly in excess of glomerular filtration rate and, in most cases, in excess of calculated renal plasma flow. Allowing for the differences in recovery from plasma and urine by different methods of analysis still makes it difficult to account for the concentrations of free dopamine observed in the urine on the basis of the filtered load of dopamine.
Source of excess dopamine found in the urine
Three main proposals have been put forward to account for the large amounts of dopamine found in human and animal urine:
1, that the kidney deconjugates dopamine compounds reaching the kidney and free dopamine is then excreted;
2, that dopamine is released from renal dopaminergic nerves;
3, that dopamine is formed in the renal tubular cells, by the action of dopa decarboxylase (L-amino acid decarboxylase) on L-dopa, and the catecholamine is then secreted into the tubular lumen.
The deconjugation hypothesis (Kuchel hypothesis)
Kuchel et al. [ 191 have put forward the hypothesis that dopamine, derived largely from the adrenal gland, is rapidly conjugated to the sulphate and glucuronide and that these compounds circulate to the kidney. Renal enzymes such as P-D-glucuronidase and arylsulphatase then deconjugate these compounds, releasing free dopamine first in the kidney substance and from there into the urine. There are a number of attractive features to this hypothesis, including the large amounts of conjugates available in the plasma that could be available for deconjugation, and also the existence of deconjugase enzymes in the kidney. However, there are a number of strong pointers against it.
(a) Ball & Lee [20] showed that the administration of carbidopa, a known peripheral dopa decarboxylase inhibitor, reduced the urine output of dopamine, at least temporarily, suggesting that a normal activity of renal dopa decarboxylase was necessary for kidney production of dopamine in man. We also showed, in the rat, that when urine free dopamine was increased, by oral salt loading (see below), rather than the excretion of the conjugates being decreased, their concentration in the urine increased in parallel with that of free dopamine, suggesting perhaps that the conjugates act as an overspill for the free catecholamine formed in the kidney.
(b) Akpaffiong [2 11 has demonstrated recently that, in rats from which both adrenal glands have been removed, it is still possible to elicit a marked increase in urine dopamine by oral salt loading. This evidence strongly suggests that the adrenal glands, a major source for circulating dopamine, do not contribute in an important way to the renal production of dopamine.
(c) The work on the renal prodrugs y-glutamyl dopa and y-glutamyl dopamine suggests that the former is a more effective source for renal dopamine production than the latter, and suggests that L-dopa may well be the major source for renal dopamine (see below).
Renal dopaminergic nerves
Bell & Lang [221 showed that stimulation of the mid-brain and hypothalamus, in anaesthetized guanethidine-treated dogs, resulted in dilatation of the renal vasculature and that this response could be attenuated by haloperidol, a known dopamine antagonist. Bell et al. [231 went on to identify dopamine-containing neuronal elements in the dog kidney. Dinerstein et al. [241, using fluorescence techniques, were able to show that the fluorescent material derived from dopamine was largely situated at the glomerular vascular pole, whereas that derived from noradrenaline was confined in the main to the periadventitial layer of the arcuate arteries. The interlobular arteries showed greater variation in fluorescence, suggesting an admixture of fibres containing either dopamine or noradrenaline. The dopaminergic fibres end in close proximity to the juxtaglomerular apparatus and may therefore be involved in the control of renin release from these cells (but see below).
It has been suggested that dopamine released into the urine might be an overspill from these renal dopaminergic nerves. This seems unlikely, in view of the rapid and effective re-uptake mechanisms present in most dopaminergic neurons, capable of the conservation of dopamine (and other catecholamines) when they are released into the synaptic cleft during nerve activation.
These dimculties can only be resolved by studying the response of the acutely and chronically denervated kidney to increased sodium chloride in the diet. Even if the renal dopaminergic nerves cannot account for a major part of the urine free dopamine, it is eminently possible that they may have an important modulating effect in the kidney both on glomerular tuft blood flow and on renin release from the juxtaglomerular cells.
Tubular production of dopamine from L-dopa
It has been known for a number of years that the kidney is an excellent source for dopa decarboxylase (aromatic L-amino acid decarboxylase, EC 4.1.1.28) 1251 and that this enzyme appears to be located in both the proximal and distal tubules [261. Ball & Lee in 1977 [201 attempted to inhibit this enzyme by the use of carbidopa and were able to show a small fall in urine dopamine. However, more studies are required on this matter with several different doses of the inhibitor.
Chan 1271 has shown, in the rat, that L-dopa is reabsorbed from the proximal renal tubule very avidly and that this active uptake process has great structural specificity. Moreover this uptake process is not affected by decarboxylase inhibitors, suggesting that it does not depend on intratubular decarboxylation mechanisms. Two groups of workers have demonstrated that the active reabsorption of L-dopa and other amino acids is dependent on the sodium concentration in the proximal tubule [28, 291. This may be one of the mechanisms whereby sodium (and chloride) concentration in the kidney can regulate the conversion of L-dopa into dopamine.
Most important evidence has been provided by
They injected tritiated L-dopa into the proximal tubules, or the peritubular space, in both innervated and denervated rat kidneys. Dopa was converted actively into urine dopamine; there was no important difference between innervated and denervated kidneys. The effectiveness of denervation was confirmed by very low tissue noradrenaline levels. Baines & Chan estimated that 3096 of urine free dopamine is derived from circulating L-dopa in the rat. However, this is a minimum estimate and does not make allowance, for example, for peptides containing dopa such as the compound y-glutamyl dopa acting as a source for dopamine. There appeared to be very little conversion of tyrosine into dopamine in innervated kidneys and this confirms the view of Nagatsu [251 that there must be very little tyrosine hydroxylase activity in the normal kidney.
Brown & Allison 13 11 have recently provided further evidence to support the theory that urine dopamine derives largely from L-dopa. After the oral administration of 250 mg of L-dopa to human volunteers, both plasma L-dopa and urine dopamine increased in similar proportion but plasma dopamine much less so. After the oral dose of L-dopa the increase in plasma L-dopa (but not in plasma dopamine) could account for the increase in urine dopamine. This gave rise to a calculated clearance for L-dopa of 114 k 20 ml/min. Moreover the kidney appeared to have sufficient decarboxylase activity to deal with increments in plasma d dopa, suggesting that conversion into dopamine was not rate-limited by enzyme but depended on the substrate concentration (Ldopa). This would add weight to the suggestion made above, that it is the uptake of Ldopa into the proximal tubule and other parts of the nephron which may be rate-limiting for conversion of L-dopa into dopamine. This step could well be sodium concentration dependent.
Finally, in this connection Ball el al.
[321 have shown, in an elegant series of experiments in the dog, that the renal source of dopamine in this animal appears to be L-dopa. By studying arteriovenous differences across the kidney they were able to demonstrate a fall in L-dopa concentration accompanied by a rise in free dopamine. The L-dopa taken up by the kidney did not appear in the urine unchanged. Presumably the L-dopa was converted into dopamine by tubular dopa decarboxylase after active uptake in the tubules.
It would seem, on balance, that the major source of renal and urinary dopamine is probably L-dopa reaching the kidney in the renal circulation. It would be most interesting to repeat the studies on arteriovenous differences across the kidney, for L-dopa and catecholamines, both in the denervated kidney and in the kidneys from dogs subjected to chronic oral salt loading, to see if the uptake of L-dopa changes under these different conditions.
These studies, taken together with those on plasma dopamine and the dopamine prodrugs, would seem to reject free plasma dopamine, or dopamine conjugates, as a major source of renal dopamine.
Renal dopaminergic prodrugs
Several groups have made use of the prodrug concept, in order to try and achieve an increased concentration of dopamine within the kidney, without at the same time producing pronounced effects on the cardiovascular system.
L y-Glutamyl dopamine
Kyncl et al. 1331 developed this compound, basing it on the hypothesis of Orlowski & Meister [341 that, because tissue y-glutamyltranspeptidase concentration is highest in the kidney, the y-glutamyl moiety would be removed there and pharmacologically effective concentrations of dopamine would then be generated intrarenally.
When administered to dogs y-glutamyl dopamine produces a protracted increase in renal blood flow but there was no stimulation of cardiac contractility or effect on the blood pressure. In the nephrectomized dog a definite rise in mesenteric vascular flow was observed, suggesting either that the compound had intrinsic residual dopaminergic activity or, alternatively, that the compound can be deglutamylated in the mesenteric vascular territory, again releasing free dopamine.
Unhydrolysed y-glutamyl dopamine is found in the circulation of the dog but after its administration concentrations of dopamine (and dopamine sulphate) are not increased, implying that extrarenal cleavage of the compound is minimal. In contrast highly significant amounts of free (and conjugated) dopamine are found in the urine, suggesting substantial renal cleavage to free dopamine (followed by conjugation). Incidentally this type of evidence would tend also to refute Kuchel's hypothesis on the source of renal and urinary dopamine (see above).
y-Glutamyl L-dopa
Wilk et al. [351 have synthesized this compound in an attempt to develop a renal dopaminergic prodrug. Dopamine is formed from the dipeptide by the sequential action of two enzymes concentrated in the kidney, y-glutamyltranspeptidase and dopa decarboxylase (aromatic L-amino acid decarboxylase). The sequence of events is as follows:
The y-glutamyl Ldopa compound differs in several major ways from y-glutamyl dopamine. First the dopa dipeptide is more rapidly hydrolysed by the transpeptidase than is the dopamine compound; second, L-dopa will then be subject to the specific active uptake mechansim described by Chan [271. Further the localization of the decarboxylase enzyme in the kidney will be an additional factor in determining the organ specificity of the L-dopa prodrug.
Wilk and his colleagues compared the two prodrugs directly in the rat and were able to demonstrate that the L-dopa derivative was five times more effective on renal plasma flow, weight for weight, than the dopamine compound. y-Glutamyl dopa also appears to have a lesser pressor effect than the dopamine dipeptide and this may be important if either of the drugs is used for the treatment of renal disorders or hypertension.
Casson and I (I. F. Casson & M. R. Lee, unpublished work) have recently used y-glutamyl dopa in an attempt to protect the kidneys of the rat from the consequences of acute renal failure induced by glycerol. Rats pretreated with the prodrug have a smaller rise in plasma creatinine, a smaller fall in urine creatinine, less histological damage and altogether seem to tolerate the toxic effects of glycerol with much less systemic upset. This suggests that dopamine, generated intrarenally, can produce renal vasodilatation and oppose the vasoconstriction induced by glycerol [361. The effectiveness of y-glutamyl dopa as a prodrug for renal dopamine also suggests, inter alia, that L-dopa can itself act as a source for renal dopamine and would therefore support the L-dopa hypothesis for the origin of renal dopamine, outlined in a previous section.
The advent of renal dopaminergic prodrugs may herald the development of substances that will prove effective in the treatment of hypertensive and oedematous disorders, characterized by low dopamine production. These, and related compounds such as ibopamine [371, may be able to exert a selective and beneficial effect on the renal vascular and tubular receptors for dopamine.
Action of dopamine on the renin-angiotensh and related systems
Renin-angiotensin
There have been several claims that dopamine can release renin from the kidney both in the intact dog [381 and in man 1391. Similar findings have been reported for the isolated perfused kidney of the rat [40] and for the kidney in vitro [411. Many of these studies can be criticized on the grounds that the doses of dopamine used were extremely high.
For example, Ball et al.
[421 have shown recently that, within the physiological dose range, dopamine is unlikely to cause renin release. At levels of dopamine 2-20 times basal plasma values there was no effect on plasma renin concentration: no significant effect was produced until levels 200 times basal were achieved. It seems very unlikely that circulating dopamine has an effect on the release of renin from the renal juxtaglomerular cells.
However, a caveat must be entered here. It was pointed out, in an earlier section, that dopaminergic endings terminate directly on the juxtaglomerular cells and it may well be that the release of renin from these cells could be blocked by dopamine or alternatively enhanced by the /I-adrenergic nerve endings (j?,-stirnulation). It is also possible that dopamine generated locally in the tubules could circulate to the juxtaglomerular cells, via the macula densa, and either cause or, indeed, prevent renin release.
Aldosterone release from the zona glomerulosa of the adrenal gland
It has been suggested that dopamine could exert a tonic inhibitory influence on aldosterone synthesis (or release) from the adrenal gland [431. When metoclopramide, a dopamine receptor antagonist, is given to man there is an increase in plasma aldosterone concentration, without a rise in plasma renin activity [441. Again it is unlikely that circulating dopamine exerts an important controlling effect in this situation but local dopaminergic mechanisms could be important. However, dopamine may act directly on the kidney to cause a polyuria in certain species. Baggio & Ferrari [481 have described a series of experiments in the rat whereby dopamine and 3,4-dihydroxyphenyIamino-2-imidazoline may stimulate a-adrenoceptors in the rat kidney, which in turn results in a sustained polyuria. Akpaffiong [211 has also suggested that there may be a separate action on water handling in the rat, independently of any action on. sodium reabsorption.
Action on the kallikrein-kinin system and the renal prostaglandins: the natriuretic cascade
Dopamine may form part of a natriuretic cascade of substances, all acting in concert to increase the kidney output of sodium (and water). Mills and his colleagues in Cambridge 149, 501 have suggested that dopamine may activate the renal kallikrein-kinin system, the renal prostaglandins and eventually the large and small molecular weight natriuretic peptides. As the renal prostaglandins such as PGE, are capable of modulating the action of exogenous vasopressin on the cortical collecting duct, this may be another mechanism by which dopamine can also affect water handling (see above).
At the moment it is difficult to assess the relative importance of intrarenal (and extrarenal) interactions between dopamine, renin, aldosterone, vasopressin and the components of the natriuretic cascade. Further work including micropuncture studies will be required in order to assess their importance.
Alteration in urine and renal tissue dopamine levels produced by extrarenal changes
Changes in urine dopamine outpul
When it became apparent that urine dopamine was disproportionately greater than could be explained by simple filtration of plasma, several groups of investigators began to study the factors that could increase urine dopamine output. A number of controlling influences have been identified: (a) changes in the electrolyte constitution of the diet; (b) infusion of sodium chloride intravenously; (c) administration of frusemide; (d) the effect of normal pregnancy; (e) the effect of the contraceptive hormone preparations.
Eflect of changes in dietary electrolytes. The first suggestion that dietary sodium could affect urinary dopamine output was seen in the work of Alexander et al. [511. In normal subjects, when dietary sodium was increased from 9 mmol to over 200 mmol/day, urine dopamine output increased from 130pg to 195 pg (mean 24 h values). When sodium chloride was infused intravenously urine dopamine increased by about 30% of basal output.
At this time (1974) it was not realized clearly that dopamine might be generated intrarenally and the results tended to be interpreted as being the result of changes in the function of adrenergic nerves. This was also true of the work of Cuche et al. [521, who showed a fall in urinary dopamine on standing.
Ball et al. [181 examined the response both of rat and man to changes in dietary electrolytes. Groups of rats were maintained on a low sodium diet under metabolic balance conditions and equimolar dietary supplements of sodium chloride, sodium bicarbonate, potassium chloride and ammonium chloride were given, to study the specificity of the previously observed increase in dopamine excretion after sodium chloride. Mean dopamine excretion increased significantly in rats given sodium chloride, potassium chloride and ammonium chloride whereas dopamine excretion decreased in those given sodium bicarbonate. These results were of interest for two principal reasons; firstly the chloride ion seemed to be important in the dopamine response; secondly, the effects of the chloride and bicarbonate salts of sodium on dopamine release parallel the effects of these ions on renin release (i.e. chloride suppresses renin more efficiently than does bicarbonate). This could perhaps suggest a common sensing mechanism for the electrolytes, perhaps through the macula densa cells of the distal convoluted tubule.
Oates et al.
[531 found, in man, that a high salt diet increased mean urine dopamine in normal volunteers from an average of 1-2 pmo1/24 h to 1.8 pmo1/24 h, plasma dopamine being essentially unchanged. In contrast, in normal volunteers given fludrocortisone, 0.2 mg twice daily, urine dopamine fell for the first few days but then rose as the individual entered the phase of escape from mineralocorticoid I541.
Infusion of isotonic sodium chloride solution and albumin. Faucheux et al. [551 have demonstrated, in the dog, that intravenous infusion of isotonic sodium chloride solution increases urine dopamine but, in contrast, giving albumin intravenously has no effect on renal dopamine output. These results are of particular interest as they suggest that the kidney can distinguish between crystalloid and colloid solutions, at least in regard to the renal production of dopamine.
Effect of frusemide on urinary production of dopamine. Kuchel and his colleagues have also shown that frusemide, when given intravenously, may increase the urinary output of dopamine significantly [141. This effect could be produced directly or indirectly. As frusemide inhibits active chloride transport in the ascending limb of the loop of Henle this could result in an increase in chloride concentration at the macula densa cells of the distal tubule. As has been pointed out in an earlier section, chloride ion concentration may be an important determinant of renal dopamine production.
Frusemide is known to be capable of increasing rend blood flow [561 and this may contribute to the diuretic effect. Both dopamine and prostaglandin production could be involved in this action on renal blood flow. It would certainly be interesting to study the effects of frusemide in animals and man, pretreated with D, receptor antagonists, to see if any part of the renal circulatory effects could be attenuated (or prevented).
Increase in urine dopamine in normal pregnancy. Our group has shown recently that urine dopamine rises in normal pregnancy from as early as week 12 of gestation and falls within 6 weeks of delivery [571. An increased renal dopamine activity in normal pregnancy may play a part in the specific renal vasodilatation of the gravid state, which results in an increase in effective renal plasma flow and glomerular filtration rate. The proximate cause for the increase in urine dopamine in pregnancy remains, at the moment, a mystery. Suspicion falls on progesterone for reasons outlined in the next paragraph.
Eflect of contraceptive hormone preparations. Perkins et al. 1571 also discovered, unexpectedly, that both the combined oral contraceptive preparation and norethisterone markedly decreased urine dopamine. This response could play a part, together with changes in the renin-angiotensin system, in the salt and water retention produced by both combined (and progestational only) antifertility agents. In contrast progesterone is natriuretic [58] . The assumption has been made that the natriuretic activity of progesterone is a result of the blockade of the renal aldosterone receptors but it is eminently possible that steroid induction of dopamine production (or inhibition of dopamine degradation) could play a part in the increased sodium loss in the urine observed after the administration of progesterone.
Studies on renal free dopamine in the rat
The studies on urine free dopamine in man, dog and rat outlined above could be criticized, if the dietary manipulations (or other manoeuvres) produced a sustained change in urine pH. The hydrion sluice theory would suggest, for example, that acidification of the urine with ammonium chloride would increase free dopamine excretion (dopamine being a weak base) whereas alkalinization of the urine with sodium bicarbonate, a strong base, would decrease the output of dopamine (the weaker base).
For these reasons it was important to prove that the changes in rat urine dopamine, produced by diet, were mirrored by parallel changes in renal tissue dopamine levels. This was shown first by Oates in my laboratory [591 and has been confirmed recently by Akpafliong 12 1 I.
Summary of the physiological evidence
It would seem likely that the kidney, in some way as yet undescribed, can monitor the concentration of crystalloids, particularly sodium, chloride, ammonium and perhaps calcium ions. The response to an increase in the concentrations of these ions is a stimulation of dopamine production. From Ball's work 1601 there does not seem to be a change in either the synthetic enzyme dopa decarboxylase or the degradative enzyme amine oxidase, within the renal tissue of the rat, to explain increased production (or decreased degradation) of the renal catecholamine. By exclusion the likely mechanism would seem to be an effect on uptake of L-dopa by the renal tubules (see above).
Another intriguing observation is the close inverse relationship between stimulation of dopamine production and inhibition of renin production (or release). Perhaps there is a common controlling link to both mechanisms through the macula densa. This will need to be resolved by micropuncture studies. Certainly the dopamine/renin ratio may be of fundamental importance in the control of salt handling by the kidney and a major determinant in the generation of raised arterial blood pressure or oedema. In some subjects with essential hypertension the control of dopamine production by sodium appears to have been lost (see below). Here it will be of great interest to determine if potassium retains its ability to increase dopamine output in these individuals. This might partially account for the saluretic effect of potassium in patients with essential hypertension 1611.
The changes in urine dopamine output during pregnancy require further dissection, in order to establish the mechanism for stimulation. Do they depend on hormonal changes or is there another vasodilator, perhaps a prostaglandin, circulating at increased concentration throughout pregnancy, perhaps capable of stimulating dopamine production in the kidney?
A role for dopamine in hypertensive and oedematous disorders?
If, on the basis of the foregoing evidence, it can be accepted that dopamine is an intrarenally generated natriuretic substance, then it could be argued that a failure, or a relative failure, in the production of this renal vasodilator catecholamine might be important, with other factors, in the genesis (and maintenance) of hypertension (or oedema). The evidence, at the moment, is no more than fragmentary but such as there is seems to point clearly in this direction.
Essential hypertension
I have argued elsewhere [621 that a subgroup of essential hypertensive subjects may exist in whom blood pressure elevation represents a failure to generate dopamine when sodium chloride is given by mouth. We have already been able to identify such individuals by their lack of a normal dopamine response [631. It would now be of great interest to administer y-glutamyl dopa, or another suitable renal dopaminergic prodrug, to individuals with this putative defect in renal dopamine production to ascertain if these compounds could lower arterial pressure significantly.
Chronic renal failure
Recently we (I. F. Casson & M. R. Lee, unpublished work) have studied a group of patients with chronic renal failure and in particular their response to an oral sodium chloride challenge. In brief, these patients have, on the whole, a low resting urinary dopamine output and when given salt they do not mobilize dopamine as efficiently as do normal individuals. This defect, together with the previously observed inability of such patients to suppress renin production completely on salt loading 1641, may play a part in the overall retention of sodium and water in chronic renal failure and result in the raised arterial pressure which often characterizes this clinical condition.
Hypertension produced by the oral contraceptives and gestatiorial hypertension
It was pointed out in an earlier section of this review that both the combined oral contraceptive (oestrogen/progestogen) and the progestogen only preparation were able to produce a marked reduction in urine dopamine output. This reduction in dopamine, taken together with the other effects of the contraceptive agents on sodium, reabsorption, and the components of the reninangiotensin system [651 may lead to sustained hypertension, perhaps, particularly, in a genetic subset of individuals prone to develop a raised arterial pressure on a volume basis.
In normal pregnancy urine dopamine rises 1571 and in pre-eclamptic toxaemia it seems to increase to levels even higher than normal [661. In contrast, in gestational hypertension in multigravidae there seems to be a relative failure to generate dopamine, although further longitudinal studies throughout pregnancy and after delivery will be required to establish this point securely. Certainly our studies on dopamine would add weight to the concept of Chesley [671 that gestational hypertension could be a form of essential hypertension occurring in pregnancy, whereas pre-eclamptic toxaemia is a separate disease sui generis.
Cyclical oedema
This disorder, almost exclusively one of women, has generated much heated controversy. about half the patients respond to this dopamine agonist. My own hunch is that this disorder really does exist and may well represent a widespread hypothalamic, adrenal and renal disorder of dopamine production (and action), together with the lack of other natriuretic factors emanating perhaps from the hypothalamus.
Summary and conclusions
It would seem established beyond peradventure that dopamine is formed in the kidney from circulating L-dopa. The likely site would appear to be the renal tubular cells but the contribution of the renal dopaminergic nerves needs further evaluation. Moreover it is probable that dopamine formed within the kidney acts there on specific receptors. This results in vasodilatation of renal blood vessels, by action on vascular receptors, and natriuresis, by an effect on tubular sodium transport mechanisms. Dopamine may form an integral part of the renal natriuretic cascade by, in its turn, evoking both the kallikrein-bradykinin system and the production of renal prostaglandins. Specific activation of the renal dopaminergic system by the administration of suitable agonists or renal prodrugs may prove possible in the future. Abnormalities in the renal production of dopamine may be important in several hypertensive and oedematous disorders. Further work will be required to establish a possible role for dopamine in these conditions and to determine whether they will benefit from treatment with suitable dopamine agonists. Dopamine, once regarded as of little importance outside the central nervous system, has certainly come to occupy a central place in renal salt handling. The ratio of dopamine production in the kidney to that for renin may be of pivotal importance in the control of systemic arterial pressure.
Perkins and Mr G. F. Cope. I also thank Dr Ball for making available to me his unpublished work on the source of renal dopamine (reference 1321).
Dr Seymour Wilk of the Mount Sinai Medical
School, New York, has given us several generous gins of y-glutamyl dopa (the renal dopaminergic prodrug).
At various times our work has been supported by the Medical Research Council, the British Heart Foundation, the Yorkshire Regional Health Authority and Sandoz Pharmaceuticals. I thank them.
